Toremifene

Revision as of 16:59, 20 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Jump to navigation Jump to search


Toremifene
Clinical data
ATC code
Pharmacokinetic data
Protein bindingmore than 99.5%
Elimination half-life5 days
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC26H28ClNO
Molar mass405.959 g/mol

WikiDoc Resources for Toremifene

Articles

Most recent articles on Toremifene

Most cited articles on Toremifene

Review articles on Toremifene

Articles on Toremifene in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Toremifene

Images of Toremifene

Photos of Toremifene

Podcasts & MP3s on Toremifene

Videos on Toremifene

Evidence Based Medicine

Cochrane Collaboration on Toremifene

Bandolier on Toremifene

TRIP on Toremifene

Clinical Trials

Ongoing Trials on Toremifene at Clinical Trials.gov

Trial results on Toremifene

Clinical Trials on Toremifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Toremifene

NICE Guidance on Toremifene

NHS PRODIGY Guidance

FDA on Toremifene

CDC on Toremifene

Books

Books on Toremifene

News

Toremifene in the news

Be alerted to news on Toremifene

News trends on Toremifene

Commentary

Blogs on Toremifene

Definitions

Definitions of Toremifene

Patient Resources / Community

Patient resources on Toremifene

Discussion groups on Toremifene

Patient Handouts on Toremifene

Directions to Hospitals Treating Toremifene

Risk calculators and risk factors for Toremifene

Healthcare Provider Resources

Symptoms of Toremifene

Causes & Risk Factors for Toremifene

Diagnostic studies for Toremifene

Treatment of Toremifene

Continuing Medical Education (CME)

CME Programs on Toremifene

International

Toremifene en Espanol

Toremifene en Francais

Business

Toremifene in the Marketplace

Patents on Toremifene

Experimental / Informatics

List of terms related to Toremifene

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.[1]

GTx Inc. is currently conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[2]

References

  1. Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer 2005;3:211-4. PMID 15882476
  2. "GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review" (Press release). GTx Inc. 2007-07-12. Retrieved 2006-07-14. Check date values in: |date= (help)

Template:Sex hormones

Template:WikiDoc Sources